BRIASETA

This brand name is authorized in Estonia, Ireland

Active ingredients

The drug BRIASETA contains one active pharmaceutical ingredient (API):

1 Ambrisentan
UNII HW6NV07QEC - AMBRISENTAN

Ambrisentan is an orally active, propanoic acid-class, ERA selective for the endothelin A (ETA) receptor. Endothelin plays a significant role in the pathophysiology of PAH.

Read about Ambrisentan

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
BRIASETA Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C02KX02 Ambrisentan C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KX Antihypertensives for pulmonary arterial hypertension
Discover more medicines within C02KX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1827851, 1827862, 1827873, 1827884, 1827895, 1827907, 1827918, 1827929

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.